Does Vical (NASDAQ:VICL) Have Gas After Even More Sellers Involved?

December 5, 2017 - By Marie Mckinney

 Does Vical (NASDAQ:VICL) Have Gas After Even More Sellers Involved?

The stock of Vical (NASDAQ:VICL) registered an increase of 104.61% in short interest. VICL’s total short interest was 519,700 shares in December as published by FINRA. Its up 104.61% from 254,000 shares, reported previously. With 198,300 shares average volume, it will take short sellers 3 days to cover their VICL’s short positions. The short interest to Vical’s float is 6.16%.

The stock decreased 1.67% or $0.03 during the last trading session, reaching $1.77. About 28,038 shares traded. Vical Incorporated (NASDAQ:VICL) has declined 38.65% since December 5, 2016 and is downtrending. It has underperformed by 55.35% the S&P500.

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company has market cap of $32.92 million. It is developing various DNA vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. It currently has negative earnings. The firm also engages in contract manufacturing of plasmid investigational products for various clients.

Vical Incorporated (NASDAQ:VICL) Ratings Coverage

Among 2 analysts covering Vical (NASDAQ:VICL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vical had 5 analyst reports since July 19, 2016 according to SRatingsIntel. As per Monday, June 12, the company rating was reinitiated by Rodman \u0026 Renshaw. The rating was maintained by H.C. Wainwright with “Buy” on Monday, June 12. The stock of Vical Incorporated (NASDAQ:VICL) earned “Buy” rating by H.C. Wainwright on Tuesday, July 19. The rating was maintained by H.C. Wainwright on Tuesday, November 21 with “Buy”. The firm has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright.

More notable recent Vical Incorporated (NASDAQ:VICL) news were published by: Globenewswire.com which released: “Vical to Provide Company Update at BIO Investor Forum Conference” on October 13, 2017, also Seekingalpha.com with their article: “Vical Incorporated’s (VICL) CEO Vijay Samant on Q2 2017 Results – Earnings …” published on August 08, 2017, Globenewswire.com published: “Vical to Host Virtual Research & Development Day on May 2, 2017” on April 24, 2017. More interesting news about Vical Incorporated (NASDAQ:VICL) were released by: Globenewswire.com and their article: “Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use …” published on October 02, 2017 as well as Globenewswire.com‘s news article titled: “Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting” with publication date: May 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.